Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced that results
from its two Phase III clinical trials of eluxadoline in patients with
diarrhea-predominant irritable bowel syndrome will be presented in a
Late-Breaking Abstract Session at Digestive Disease Week (DDW) 2014, to
be held May 3-6 at McCormick Place in Chicago, IL.
Details of the presentation are as follows:
Abstract Title:
|
|
Eluxadoline for the Treatment of Diarrhea-Predominant Irritable
Bowel Syndrome: Results of 2 Randomized, Double-blind,
Placebo-Controlled Phase 3 Clinical Trials of Efficacy and Safety
|
Abstract Number:
|
|
929d
|
Session Title:
|
|
Clinical Late Breaking Abstract Session
|
Presenter:
|
|
Anthony J. Lembo, M.D., Associate Professor of Medicine, Harvard
Medical School, Beth Israel Deaconess Medical Center
|
Session Date:
|
|
May 6, 2014
|
Presentation Time:
|
|
10:45 a.m. to 11:00 a.m. CT
|
About Digestive Disease Week
Digestive Disease Week® (DDW®) is the largest international gathering of
physicians, researchers and academics in the fields of gastroenterology,
hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by
the American Association for the Study of Liver Diseases (AASLD), the
American Gastroenterological Association (AGA) Institute, the American
Society for Gastrointestinal Endoscopy (ASGE) and the Society for
Surgery of the Alimentary Tract (SSAT), DDW takes place May 3 – 6, 2014,
at McCormick Place, Chicago, IL. The meeting showcases more than 5,000
abstracts and hundreds of lectures on the latest advances in
gastrointestinal research, medicine and technology. More information can
be found at www.ddw.org.
About Eluxadoline
Eluxadoline is a novel, orally active investigational agent with
combined mu opioid receptor agonist and delta opioid receptor antagonist
activity which acts locally in the gut and has very low oral
bioavailability. This dual opioid activity is designed to treat diarrhea
and pain symptoms of IBS-d, without causing the constipating side
effects that can occur with unopposed mu opioid agonists. Eluxadoline
treatment was demonstrated to show simultaneous improvements in stool
consistency and abdominal pain in two Phase III clinical trials.
Eluxadoline has been granted Fast Track status by the FDA, a process
designed to facilitate development and expedite the review of drugs to
treat diseases with significant unmet medical need.
About Furiex
Furiex Pharmaceuticals is a drug development collaboration company that
uses innovative clinical development design to accelerate and increase
value of drug development programs by advancing them through the drug
discovery and development process in a cost-efficient manner. Our drug
development programs are designed and driven by a core team with
extensive drug development experience. The Company collaborates with
pharmaceutical and biotechnology companies and has a diversified product
portfolio and pipeline with multiple therapeutic candidates, including
one Phase III-ready asset, two compounds in Phase III development, one
of which is with a partner, and four products on the market. The
Company's mission is to develop innovative medicines faster and at a
lower cost, thereby improving profitability and accelerating time to
market while providing life-improving therapies for patients. For more
information, visit www.furiex.com.
Except for historical information, all of the statements,
expectations and assumptions contained in this news release are
forward-looking statements that involve a number of risks and
uncertainties. Although Furiex attempts to be accurate in making these
forward-looking statements, it is possible that future circumstances
might differ from the assumptions on which such statements are based. In
addition, other important factors which could cause actual results to
differ materially include the following: progress of compounds in
clinical trials and regulatory approvals; potential changes to
regulatory guidance by regulatory agencies such as the U.S. Food and
Drug Administration and the European Medicines Agency; the risk of
finding a collaborator for our late-stage compounds, or risks involved
in our attempting to commercialize compounds ourselves; continuing
losses and our potential need for additional financing; the risks and
expense of continuing the research and development activities of our
existing compounds; inability of collaborators to effectively market
approved products for which we receive royalty and sales-based milestone
payments; changes in the safety and efficacy profile of our existing
compounds as they progress through research and development; new
collaborative agreements that we might enter into in the future; the
costs of defending any patent opposition or litigation necessary to
protect our proprietary technologies; and the other risk factors set
forth from time to time in the SEC filings for Furiex, copies of which
can be found on our website.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20140403006395r1&sid=ntxv4&distro=nx)
Copyright Business Wire 2014